Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Alex Braun - Head-Investor Relations Dan O'Connell - Chief Executive Officer Eric Siemers - Chief Medical Officer Matt Zuga - Chief Financial Officer & Chief Business Officer Conference Call Participants Colin Bristow - UBS Paul Matteis - Stifel Tom Shrader - BTIG Pete Stavropoulos - Cantor Fitzgerald Charlie Yang - Bank of America Operator Thank you for standing by, and welcome to the ...

Q2 2023 Financial Results & Business Update August 8, 2023 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking stateme ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________ FORM 10-Q ___________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-40551 ___________________________ Acumen Pharmaceuticals, ...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO and Chief Business Officer Conference Call Participants Tom Shrader - BTIG Judah Frommer - Credit Suisse Charlie Yang - BofA Operator Good day, and thank you for standing by. Welcome to the Acumen Pharma Q1 2023 Conference Call and Webcast. At this time all participants are in a l ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________ FORM 10-Q ___________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-40551 ___________________________ Acumen Pharmaceuticals ...

1 FY 2022 Financial Results & Business Update March 27, 2023 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "believes," "expects," "anticipates," "could," "would," "seeks," "aims," "plans," "potential, ...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2022 Earnings Conference Call March 27, 2023 8:00 AM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and Chief Executive Officer Eric Siemers - , Chief Medical Officer Matt Zuga - Chief Financial Officer and Chief Business Office Conference Call Participants Paul Matteis - Stifel Tom Shrader - BTIG Judah Frommer - Credit Suisse Operator Thank you for standing by. Welcome to Acumen Pharmaceuticals Full Year 2022 Conference Call and Webca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________ FORM 10-K __________________________ x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2022 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-40551 __________________________ Acumen Pharmaceuticals, Inc. (Exact name of registrant ...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and CEO Eric Siemers - CMO Matt Zuga - CFO and CBO Conference Call Participants Tom Shrader - BTIG Judah Frommer - Credit Suisse Charlie Yang - Bank of America Operator Good day. Thank you for standing by. Welcome to the Acumen Pharmaceuticals, Q3 2022 Conference Call and Webcast. At this time, all participants are in a listen-only mo ...